ClinicalTrials.gg
CompletedNCT00800800ASTRONOMERUpdated Dec 3, 2010

Effects of Rosuvastatin on Aortic Stenosis Progression

A Phase 3 interventional study of Rosuvastatin and Placebo in Aortic Stenosis, sponsored by AstraZeneca. Completed at 15 sites in Canada. Open to participants aged 18 Years to 82 Years. Per ClinicalTrials.gov, last updated 2010-12-03.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
378
Allocation
Randomized
Ages
18 Years to 82 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies in Aortic Valve Stenosis with a site in Canada — 23 open to participants now, 36 under way, 1 of them phase 3. Aortic Valve Stenosis · Canada.

Planned enrollment
28th of 60
378 · median 300
Started
2002
with 1 other
Phase 3
5 of 87
none open now
Registered
4th of 87
by date

Among the 87 studies in Aortic Valve Stenosis with a site in Canada, this one is the 28th largest by planned enrollment of the 60 interventional ones that give a count, is one of 2 that started in 2002, is one of 5 in phase 3, and was the 4th registered.

Aortic Valve Stenosis

1,026 studies on the registry are indexed under Aortic Valve Stenosis; 294 are open to participants now.

Browse Aortic Valve Stenosis studies →

Open to participants now

23 of the 87 studies in Aortic Valve Stenosis with a site in Canada are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 25 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 82 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Aortic Valve Stenosis with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effects of rosuvastatin compared to usual care in patients diagnosed with aortic valvular stenosis. Patients must have a diagnosis of mild to moderate aortic stenosis (AS) and no clinical indication for the use of cholesterol lowering agents. A multi-centre, randomized, double-blind, placebo-controlled study, with a two year recruitment period, and a treatment duration of a minimum of 3 years from the time of the last patient randomized to a maximum of 5 years.

03

Conditions studied

  • Aortic Stenosis

Keywords

  • progression of aortic stenosis
04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate AS defined by peak Doppler aortic valve velocity 2.5 to 4 m/sec
  • Baseline LDL-C value must be within targeted level for all risk categories according to the Canadian Guidelines
  • Baseline triglyceride levels must be within target level for the risk categories

Exclusion criteria

Exclusion Criteria:

  • Very mild AS defined by peak Doppler AS velocity \<2.5m/sec, because the rate of progression is not well defined; Females of child bearing potential who do not practice adequate .
  • Severe AS defined by peak Doppler AS velocity > 4m/sec. These patients are excluded because they will have a high probability of aortic valve replacement even without further AS progression.
  • Greater than moderate aortic regurgitation, defined as aortic jet width to aortic outflow tract ratio >0.45; Patients with diabetes or with a fasting blood sugar level > 7.0 mmol/L (must be confirmed with one repeat assay within 14 days).
  • Significant concomitant mitral valve disease, defined by > moderate mitral regurgitation (MR) or mitral valve area (MVA)\< 1.5 cm2; A very high risk of CAD (10 year risk > 30%), according to the Canadian Guidelines.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
378 participants (estimated)

Study arms

  • Active comparator
    1

    Rosuvastatin 40 mg

    Drug: Rosuvastatin

  • Placebo comparator
    2

    placebo

    Drug: Placebo

Interventions

  • 40 mg, oral, single dose

  • DrugPlacebo

    oral, single dose

06

What researchers measure

Primary outcomes

  1. The changes in transvalvular aortic velocities and the changes in aortic valve area.

    Time frame: Between baseline and close-out measurments.

Secondary outcomes

  1. The incidence and severity of adverse events, the clinically relevant changes in echocardiograms, and laboratory analysis will be compared between the two treatment groups.

    Time frame: Baseline and minimum of 3 year follow-up.

  2. The incidence and severity of adverse events, the clinically relevant changes in echocardiograms, and laboratory analysis will be compared between the two treatment groups.

    Time frame: Between baseline and close-out measurments.

07

Study locations

15 sites
  • Research site
    Calgary, Alberta, Canada
  • Research site
    Edmonton, Alberta, Canada
  • Research site
    Surrey, British Columbia, Canada
  • Research site
    Vancouver, British Columbia, Canada
  • Research site
    Victoria, British Columbia, Canada
  • Research site
    Edmonton, Manitoba, Canada
  • Research site
    Brampton, Ontario, Canada
  • Research site
    Cambridge, Ontario, Canada
  • Research site
    Kitchener, Ontario, Canada
  • Research site
    Montreal, Ontario, Canada
  • Research site
    Ottawa, Ontario, Canada
  • Research site
    Toronto, Ontario, Canada
  • Research site
    Montreal, Quebec, Canada
  • Research site
    Halifax, Canada
  • Research site
    St. John's, Canada
08

References and documents

Publications

  • Capoulade R, Torzewski M, Mayr M, Chan KL, Mathieu P, Bosse Y, Dumesnil JG, Tam J, Teo KK, Burnap SA, Schmid J, Gobel N, Franke UFW, Sanchez A, Witztum JL, Yang X, Yeang C, Arsenault B, Despres JP, Pibarot P, Tsimikas S. ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. Heart. 2020 May;106(10):738-745. doi: 10.1136/heartjnl-2019-315840. Epub 2020 Feb 13. PubMed 32054669 ↗
  • Capoulade R, Yeang C, Chan KL, Pibarot P, Tsimikas S. Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol. 2018 Dec 1;3(12):1212-1217. doi: 10.1001/jamacardio.2018.3798. PubMed 30476957 ↗
  • Capoulade R, Chan KL, Mathieu P, Bosse Y, Dumesnil JG, Tam JW, Teo KK, Yang X, Witztum JL, Arsenault BJ, Despres JP, Pibarot P, Tsimikas S. Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. Atherosclerosis. 2017 May;260:1-7. doi: 10.1016/j.atherosclerosis.2017.03.013. Epub 2017 Mar 9. PubMed 28319871 ↗
  • Capoulade R, Chan KL, Yeang C, Mathieu P, Bosse Y, Dumesnil JG, Tam JW, Teo KK, Mahmut A, Yang X, Witztum JL, Arsenault BJ, Despres JP, Pibarot P, Tsimikas S. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. J Am Coll Cardiol. 2015 Sep 15;66(11):1236-1246. doi: 10.1016/j.jacc.2015.07.020. PubMed 26361154 ↗
  • Page A, Dumesnil JG, Clavel MA, Chan KL, Teo KK, Tam JW, Mathieu P, Despres JP, Pibarot P; ASTRONOMER Investigators. Metabolic syndrome is associated with more pronounced impairment of left ventricle geometry and function in patients with calcific aortic stenosis: a substudy of the ASTRONOMER (Aortic Stenosis Progression Observation Measuring Effects of Rosuvastatin). J Am Coll Cardiol. 2010 Apr 27;55(17):1867-74. doi: 10.1016/j.jacc.2009.11.083. PubMed 20413039 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 25, 2008
First posted
Dec 2, 2008
Start
Nov 2002
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Last update
Dec 3, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00800800
Lead sponsor
AstraZeneca
First posted
Dec 2, 2008
Start date
Nov 2002
Primary completion
Sep 2008
Completion
Sep 2008
Last update
Dec 3, 2010

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion